Why the study?
Differences in door-to-balloon time and clinical outcomes in STEMI patients undergoing primary PCI after SARS-CoV-2 infection were not well known.
Does SARS-CoV-2 positivity worsen door-to-balloon time and in-hospital mortality in STEMI patients undergoing primary percutaneous coronary intervention?
Meta-Analysis (n=2,111)
Does SARS-CoV-2 positivity worsen door-to-balloon time and in-hospital mortality in STEMI patients undergoing primary percutaneous coronary intervention?
Odds Ratio: 6.31 (95% CI 0.99–11.63)
p-value: p=0.02
SARS-CoV-2 infection in STEMI patients undergoing primary PCI is associated with significant delays in door-to-balloon time and a more than 5-fold increase in in-hospital mortality.
BACKGROUND: The coronavirus disease 2019 infection has significantly impacted the world and placed a heavy strain on the medical system and the public, especially those with cardiovascular diseases. Hoverer, the differences in door-to-balloon time and outcomes in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are not known too much. METHODS: Web of Science, EMBASE, PubMed, Cochrane Library, Wanfang, VIP, and China's National Knowledge Infrastructure were utilized to perform a systematic literature search until April 30, 2023. We computed the odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) to determine the correlation. A random-effects model was used for the meta-analysis if the study had significant heterogeneity. Meanwhile, sensitivity analysis and Trial sequential analysis were also accomplished using Rveman5.4 and trial sequential analysis 0.9.5.10 Beta software, respectively. RESULTS: A total of 5 eligible studies were explored in our meta-analysis, including 307 cases and 1804 controls. By meta-analysis, the pooled data showed that SARS-CoV-2-positive STEMI patients undergoing percutaneous coronary intervention had a longer door-to-balloon time (OR 6.31, 95% CI 0.99, 11.63, P = .02) than the negative subjects. The glycoprotein IIb/IIIa inhibitor use after SARS-CoV-2 infection (OR 2.71, 95% CI 1.53, 4.81, P = .0006) was relatively frequent compared with controls, and the postoperative Thrombolysis in Myocardial Infarction blood flow (OR 0.48, 95% CI 0.34, 0.67, P < .0001) was worse compared that. The in-hospital mortality (OR 5.16, 95% CI 3.53, 7.53, P < .00001) was higher than non-SARS-CoV-2 infection ones. In addition, we also discovered that age, gender (male), hypertension, diabetes mellitus, hyperlipidemia, smoking, previous myocardial infarction, total ischemia time, and thrombus aspiration use did not have a significant association with the development of STEMI patients with SARS-CoV-2. CONCLUSION: SARS-CoV-2 positivity is significantly associated with longer door-to-balloon time and higher in-hospital mortality in STEMI patients undergoing primary percutaneous coronary intervention.
No takes yet. Share an insight, caveat, or question.
Bao et al. (2023) conducted a meta-analysis in ST-segment elevation myocardial infarction (STEMI) (n=2,111). SARS-CoV-2 infection vs. SARS-CoV-2 negative subjects was evaluated on door-to-balloon time (OR 6.31, 95% CI 0.99-11.63, p=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: